渤健公司近日在阿尔茨海默病协会国际会议上公布了其候选药物Diranersen的Celia二期研究数据。结果显示，该药物在治疗早期阿尔茨海默病患者时，不仅带来了具有临床意义的积极结局，更实现了Tau蛋白水平的强劲降低。这一积极信号为针对这一复杂神经退行性疾病的靶向治疗带来了新的希望。
渤健公司近日在阿尔茨海默病协会国际会议上公布了其候选药物Diranersen的Celia二期研究数据。结果显示，该药物在治疗早期阿尔茨海默病患者时，不仅带来了具有临床意义的积极结局，更实现了Tau蛋白水平的强劲降低。这一积极信号为针对这一复杂神经退行性疾病的靶向治疗带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.